Cardiovascular Risk Screening and Risk Reduction in Women Vets
Cardiovascular Diseases, Hypertension, Hyperlipidemias
About this trial
This is an interventional health services research trial for Cardiovascular Diseases focused on measuring Patient Participation [N05.300.150.600.620], Health Behavior [F01.145.488], Women [M01.975], Patient Satisfaction [N05.715.360.600], Physicians, Primary Care [M01.526.485.810.800], Physicians, Women [M01.526.485.810.820], Health Educators [M01.526.485.410], Cardiovascular Diseases [C14], Hypertension [C14.907.489], Hyperlipidemias [C18.452.584.500.500], Dyslipidemias [C18.452.584.500], Obesity [C18.654.726.500], Diabetes Mellitus [C18.452.394.750], Tobacco Use Disorder [C25.775.912], Overweight [C23.888.144.699]
Eligibility Criteria
Inclusion Criteria:
- For Patient Activities: Women VA patients with any cardiovascular risk factors
- For Key Stakeholder Activities: VA staff affiliated with the Women's Health Clinic
Exclusion Criteria:
- For Patient Activities: Men & Patients with cognitive impairment precluding informed consent
- For Key Stakeholder Activities: non- VA staff
Sites / Locations
- VA Greater Los Angeles Healthcare System, Sepulveda, CA
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT
- South Texas Health Care System, San Antonio, TX
Arms of the Study
Arm 1
Other
Arm 1
The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is "turned on" when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention.